Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Ghosh A, Heston W. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39.

Article  CAS  PubMed  Google Scholar 

Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.

Article  PubMed  Google Scholar 

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch M, De Santis M, Fossati N, Gross T, Henry A, Joniau S, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1 screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

Article  PubMed  Google Scholar 

Ferraro DA, Garcia Schüler HI, Muehlematter UJ, Eberli D, Müller J, Müller A, Gablinger R, Kranzbühler H, Omlin A, Kaufmann PA, et al. Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(3):652–64.

Article  CAS  PubMed  Google Scholar 

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, Nelson C, Chung E, Wood G, Malone G, et al. Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of Multiparametric magnetic resonance imaging in localized prostate cancer. J Urol. 2016;196(4):1261–7.

Article  CAS  PubMed  Google Scholar 

Donin N, Reiter R. Why targeting PSMA is a game changer in the management of prostate cancer. J Nuclear Medicine: Official Public, Soc Nuclear Medic. 2018;59(2):177–82.

Article  Google Scholar 

Chandekar KR, Singh H, Kumar R, Kumar S, Kakkar N, Mittal BR, Singh SK. Comparison of 18F-PSMA-1007 PET/CT with 68Ga-PSMA-11 PET/CT for initial staging in intermediate- and high-risk prostate cancer. Clin Nucl Med. 2023;48(1):e1–8.

Article  PubMed  Google Scholar 

Giesel F, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88.

Article  CAS  PubMed  Google Scholar 

Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Kusters-Vandevelde HVN, Wijers CHW, Somford DM, van Basten JA. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Eur J Nucl Med Mol Imaging. 2022;49(11):3929–37.

Article  CAS  PubMed  Google Scholar 

Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, et al. A Prospective Comparison of (18)F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2021;4(4):635–44. https://doi.org/10.1016/j.euo.2020.06.012.

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, et al. Intraindividual comparison of (18)F-PSMA-1007 PET/CT, Multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate Cancer: a retrospective. Proof-of-Concept Study J Nucl Med. 2017;58(11):1805–10.

Article  CAS  PubMed  Google Scholar 

Toriihara A, Nobashi T, Baratto L, Duan H, Moradi F, Park S, Hatami N, Aparici CM, Davidzon G, Iagaru A. Comparison of 3 interpretation criteria for (68)Ga-PSMA11 PET based on inter- and intrareader agreement. J Nucl Med. 2020;61(4):533–9.

Article  CAS  PubMed  Google Scholar 

Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, Oprea-Lager DE, Oyen WJ, Rouvière O, Mottet N, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469–76.

Article  PubMed  Google Scholar 

Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, Makowski MR, Brenner W, Prasad V. Immunohistochemical validation of PSMA expression measured by (68)Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med. 2018;59(2):238–43.

Article  CAS  PubMed  Google Scholar 

Wang Z, Zheng A, Li Y, Dong W, Liu X, Yuan W, Gao F, Duan X. 18F-PSMA-1007 PET/CT Performance on risk stratification discrimination and distant metastases prediction in newly diagnosed prostate cancer. Front oncol. 2021;11:759053.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D’Amico AV. Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens Validation in a cohort of 434 patients. Am J Clin Pathol. 1999;111(5):641–4.

Article  CAS  PubMed  Google Scholar 

Cytawa W, Kircher S, Kübler H, Werner R, Weber S, Hartrampf P, Bandurski T, Lass P, Połom W, Matuszewski M, et al. Diverse PSMA expression in primary prostate cancer: reason for negative [Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens. Eur J Nucl Med Mol Imaging. 2022;49(11):3938–49.

Article  CAS  PubMed  Google Scholar 

Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117–36.

Article  PubMed  Google Scholar 

Chikatamarla VA, Okano S, Jenvey P, Ansaldo A, Roberts MJ, Ramsay SC, Thomas PA, Pattison DA. Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging. EJNMMI Res. 2021;11(1):128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156–61.

Article  CAS  PubMed  Google Scholar 

Rauscher I, Krönke M, König M, Gafita A, Maurer T, Horn T, Schiller K, Weber W, Eiber M. Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61(1):51–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

Article  CAS  PubMed  Google Scholar 

Prive BM, Israel B, Schilham MGM, Muselaers CHJ, Zamecnik P, Mulders PFA, Witjes JA, Sedelaar M, Mehra N, Verzijlbergen F, et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2021;24(2):423–30.

Article  PubMed  Google Scholar 

Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, et al. Head-to-Head Comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with a Histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63(6):847–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tragardh E, Simoulis A, Bjartell A, Jogi J. Tumor detection of (18)F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method. J Nucl Med. 2021;62(12):1735–40.

Article  CAS  PubMed  PubMed Central  Google Scholar